Telluride Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Telluride Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	$537K	Buy	+8,507	New	+$506K	0.46%	79

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Telluride Asset Management's ALNY Position: Q2 2014 in Review

Telluride Asset Management opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2014: 8,507 shares worth $537K. The stake represents 0.46% of the portfolio and ranks #79 among its holdings.

194 funds tracked by Wall St. Rank hold ALNY as of Q2 2014.

Telluride Asset Management held 8,507 shares of Alnylam Pharmaceuticals worth $537K as of Q2 2014.
Alnylam Pharmaceuticals was a new Telluride Asset Management position in Q2 2014.
Alnylam Pharmaceuticals made up 0.46% of Telluride Asset Management's portfolio in Q2 2014, its #79 holding.
194 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2014.

Based on Telluride Asset Management's 13F filing for Q2 2014, filed 14 Aug 2014.